Pure Global
NCT04646252

The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events

Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6 Year Follow up Study
University of Athens·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Endothelial Dysfunction
Drug/Device/Intervention
Perfused Boundary Region of sublingual microvessels
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
University of Athens
Location
Athens, Greece
Timeline & enrollment
Phase
N/A
Start date
Jan 10, 2013
End date
Mar 28, 2023
Enrollment
500 participants
Primary outcome

Major Adverse Cardiovascular events

Summary

We intend to recruit individuals who are referred for a routine screening in the primary
 prevention outpatient clinic of Attikon University hospital, Athens According to
 institutional protocols, a detailed medical history for atherosclerotic risk factors and
 current medication is recorded and a baseline clinical examination is performed. Moreover
 fasting blood samples are drawn to diagnose the presence of diabetes mellitus and
 hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are
 revaluated at one month and then followed up according to the attending physician's
 instructions. All subjects are followed up for adverse events (death, stroke, myocardial
 infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic
 contact and planned appointment at the outpatient clinic.

ICD-10 classifications
Other peripheral vascular diseasesAtherosclerosis of arteries of extremitiesOther specified peripheral vascular diseasesRenovascular hypertensionOther disorders of arteries and arterioles
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04646252
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04646252 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Athens and is currently Recruiting. The study focuses on Endothelial Dysfunction. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.